How compounded semaglutide and tirzepatide differ from FDA-approved versions, what changed when the 2025 shortages ended, and the safety questions to ask.
Few topics generate more confused questions in my office than this one: “Is the compounded version the same as the real thing?” It’s a fair question, because for a couple of years compounded semaglutide and tirzepatide were sold almost everywhere — online, in wellness clinics, even through social media ads — and the rules around them have shifted more than once.
In this article I’ll explain what compounding is, why it became so common, what changed when the FDA declared the shortages over, and the specific questions I encourage every patient to ask before starting any GLP-1 medication, wherever they get it.
An FDA-approved GLP-1 medication has gone through large randomized clinical trials, and the agency has reviewed not only whether the drug works but how it’s manufactured. The approved product is made in inspected facilities, with a defined active ingredient, tested purity and potency, a validated injection device, and a label that spells out dosing, side effects and warnings.
When I prescribe semaglutide or tirzepatide as an approved product, I know exactly what molecule is in the pen and how much of it. That certainty matters with drugs that are dosed in fractions of a milligram.
Compounding is the preparation of a medication by a pharmacy to meet a specific need. It has a legitimate place in medicine: a patient who is allergic to a dye in a commercial tablet, or a child who needs a liquid form of a drug that only comes as a pill.
Federal law generally does not allow pharmacies to make routine copies of commercially available approved drugs. The exception that mattered here is the drug shortage provision. While semaglutide and tirzepatide were on the FDA’s shortage list, compounding pharmacies were permitted to make versions of them. Demand far outstripped supply, and compounded products filled the gap.
The FDA determined that the tirzepatide shortage was resolved in late 2024 and that the semaglutide shortage was resolved in February 2025. The agency then gave compounders a limited transition period, which ended in spring 2025. Since then, making what the law calls “essentially a copy” of these drugs is generally no longer permitted. A narrow exception remains for an individual patient whose prescriber documents a clinically significant need that the approved product can’t meet — for example, a true allergy to an inactive ingredient.
Some sellers have continued to market products with added vitamins or unusual doses as “personalized.” Whether a particular product is lawful is a regulatory question I can’t answer for any given pharmacy, but the change should prompt careful questions.
Compounded drugs are not reviewed by the FDA for safety, effectiveness or quality before they reach patients. That doesn’t mean every compounded product is dangerous, but it means the burden of trust shifts to the pharmacy. The concerns the FDA has publicly raised include:
From my nephrology background, I’ll add one more: dehydration from GI side effects can injure the kidneys. An accidental overdose isn’t only unpleasant — it can be medically serious.
Regardless of source, these medications aren’t right for everyone. They are not appropriate for people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2, and they call for caution in people with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, or diabetic eye disease. They should not be used during pregnancy. Anyone with a history of an eating disorder deserves a careful, individualized conversation first.
If you develop severe abdominal pain, persistent vomiting, signs of dehydration, or yellowing of the skin, seek medical care promptly.
Not necessarily. It has not been reviewed by the FDA for quality or equivalence, and some versions have used different salt forms. The approved product is the only version with trial data behind it.
Since the shortage ended and the transition period closed in 2025, routine copies are generally not permitted. Limited individual exceptions exist when a prescriber documents a clinically significant need.
Brand pricing reflects development and manufacturing costs. Insurance coverage and manufacturer programs vary, and a consultation is a good time to review realistic options.
Contact your prescriber or poison control, and seek urgent care for severe vomiting, inability to keep fluids down, or dizziness.
If you’re weighing medical weight loss and want clear information about which medications are appropriate for you, I invite you to schedule a complimentary, no-commitment consultation. Our program is overseen by trained medical professionals under my supervision.
Ask about Easy Pay financing.
References: U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. FDA. 2025. · Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021. · Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022. · U.S. Food and Drug Administration
This article is for general information only and is not medical advice. Treatments are provided only after consultation and evaluation by a licensed provider. Individual results vary.
A scale rolls fat, muscle and water into one number and lets it set your mood. Body composition breaks that number into its parts, and the parts are what actually change when a plan is working.
A GLP-1 medication changes how much you eat. What you eat, how you move and how you care for your skin decide how you look and feel at the end.
Losing weight quickly can leave the face looking older than you feel. Here’s why “GLP-1 face” happens, how to limit it, and the treatments that can help.